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Abstract
Background and objective: Asthma is characterized by airway hyperreactivity and airway 
inflammation. We previously demonstrated that adults with mild well-controlled asthma exhibited 
a marked decrease in airway reactivity (PC20 increased >2-fold) after using nocturnal continuous 
positive airway pressure (CPAP) for 1 week. If CPAP produces a similar suppression of airway 
reactivity in children with moderate–severe asthma, who require chronic use of corticosteroids, 
then this non-pharmacological therapy might provide a beneficial alternative or supplemental 
therapy in these subjects.
Methods: Children aged 8–17 years with moderate–severe asthma were treated with 4 weeks of 
nocturnal CPAP (8–10 cm H2O) or sham CPAP (<2 cm H2O). Adherence was monitored with a 
modem installed in the equipment or by memory cards. Airway reactivity, assessed by 
methacholine bronchial challenge, was measured prior to and following treatment.
Results: The percentage of subjects adherent to treatment was similar in both groups (19/27 
CPAP vs 19/28 sham, ~70%). There was a tendency for PC20 to increase with treatment in both 
groups (3.0–5.3 mg/mL CPAP vs 3.2 to 4.3 mg/mL sham, P = 0.083); however, the change did not 
differ significantly between groups (P = 0.569).
Conclusion: We found that the 4-week treatment with nocturnal CPAP did not produce a 
twofold suppression of airway reactivity in children with moderate–severe asthma.
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INTRODUCTION
Mechanical strain imposed on the lungs during breathing is an important modulator of 
airway responsiveness in vivo1; deep inspirations and tidal breathing decrease airway 
responsiveness in healthy adults and animals.2–6 Our laboratory previously demonstrated in 
animals that sustained mechanical strain of the airways using continuous positive airway 
pressure (CPAP) decreased airway reactivity in vivo and ex vivo.7–9 In a small clinical trial, 
we demonstrated that adults with mild well-controlled asthma exhibited a marked decrease 
in airway reactivity after using nocturnal CPAP for 1 week; the methacholine (MCh) 
concentration to decrease forced expiratory volume in 1 s (FEV1) by 20% more than 
doubled.10 Currently, there are no studies evaluating whether CPAP suppresses airway 
reactivity in children, particularly those with moderate–severe disease, who require chronic 
use of inhaled corticosteroids (ICS) and systemic corticosteroids for frequent exacerbations. 
If CPAP markedly suppresses airway reactivity in these children, this non-pharmacological 
therapy might provide a beneficial alternative or supplemental therapy for children with high 
respiratory morbidity and risk of steroid associated growth suppression. Our recent in vitro 
studies have also demonstrated that mechanical strain of isolated airway smooth muscle 
(ASM) suppresses the inflammatory response of ASM to IL-13 stimulation11,12; however, 
there have been no in vivo studies. Therefore, we hypothesized that nocturnal CPAP for 4 
weeks would markedly suppress airway reactivity, as well as airway inflammation, in 
children with moderate–severe asthma.
METHODS
Study population
Children aged 8–17 years with moderate–severe asthma, defined by National Asthma 
Education and Prevention Program/Expert Panel Report (NAEPP)/EPR III guidelines of 
treatment steps 4 and 5, were recruited at Riley Hospital for Children, Indianapolis, IN.13 
Study exclusion criteria included: body mass index (BMI) >95th percentile; other chronic 
lung disease; history of pneumothorax; congenital heart disease; obstructive sleep apnoea; 
baseline FEV1 < 70% predicted; bronchial challenge test with an MCh concentration > 16 
mg/mL to decrease FEV1 by 20% (PC20).
The study was approved by the Institutional Review Board at Indiana University (ID# 
1404809731). Subjects were recruited between 2015 and 2017. Informed parental consent 
and subject assent were obtained. The study was registered on ClinicalTrials.gov ().
Study design
Treatment—Subjects had two study visits (V1 and V2). The study was single-blinded 
(subjects were blinded to treatment group, but not all researchers). The research coordinator 
who performed the study measurements, as well as instructed subjects on use of the CPAP 
equipment, was not blinded to treatment. At V1, qualified subjects were alternately allocated 
to CPAP (8–10 cm H2O) or sham CPAP (<2 cm H2O) treatment and instructed to use the 
assigned treatment every night for a total of 28 ± 3 days. There was telephone follow-up in 
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the first 3 days to assess if parents had been able to set up the equipment at home, as well as 
weekly telephone follow-up. Assessment was repeated at V2.
Adherence to equipment use was assessed by the machine modem or memory card. For an 
asthma exacerbation requiring oral corticosteroids during the study period, CPAP or sham 
was extended for 21 days after the last corticosteroid dose. At V2, a subject was considered 
adherent with treatment if an average of ≥4 h/night and ≥5 days/week for all 4 weeks was 
achieved, and if treatment was used for ≥4 h on the two nights before V2.
Measurements—Asthma symptom score was assessed using the Asthma Control Test 
(ACT)14; higher scores indicate better control. Exhaled nitric oxide (eNO) was measured 
using a chemiluminescence analyser (NIOX; Aerocrine Inc., Morrisville, NC, USA).15 
Spirometry was obtained with bronchodilators withheld on the day of evaluation16 
(ComPAS; Morgan Scientific Inc., Haverhill, MA, USA). MCh bronchial challenge was 
performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) 
with quadrupling concentrations starting with 0.0625 mg/mL and continuing until FEV1 
decreased by 20% (PC20) or MCh concentration of 16 mg/mL was inhaled.17 Induced 
sputum was obtained after the MCh challenge and treatment with albuterol to return FEV1 to 
≥70% predicted. Subjects inhaled increasing concentrations of hypertonic saline (3%, 4%, 
5% and 7%) at 5-min intervals using a breath actuated nebulizer (AeroEclipse; Monaghan, 
Plattsburgh, NY, USA) coupled with a device that generates oscillating positive expiratory 
pressure to improve lower airway clearance (Aerobika; Monaghan). Sputum was processed 
for total cell count and cell viability was determined by trypan blue exclusion. Only samples 
with cell viability ≥50% and squamous cells ≤20% were considered acceptable.18,19 Cell-
free supernatant was frozen for cytokine analysis (Luminex 200).
Statistical analysis
The primary outcome was the change in airway reactivity (PC20) between V1 and V2. 
Sample size was calculated based on the difference of logPC20 changes between groups 
using our previous study in adults with mild asthma; there was a difference of change in 
logPC20 between CPAP and sham groups as 0.41, with an SD of 0.46.13 With this effect 
size, variability and 10% subject dropout, we estimated that 30 subjects would result in more 
than 85% power to detect such a difference with a 5% Type I error rate using a two-sample t-
test.
Secondary outcomes included the changes in airway inflammatory markers (eNO, % 
eosinophils and cytokine concentrations in induced sputum), FEV1 (% predicted) and ACT 
scores. Demographic characteristics and baseline results of CPAP and sham groups were 
compared using Student’s t-tests for continuous normal variables, Wilcoxon–Kruskal–Wallis 
non-parametric tests for non-normal variables, and chi-square tests for categorical variables. 
We utilized Generalized Linear Models (GLM) so that the analytic assumptions would be 
met, even when the data were not normally distributed. We tested the main effects of time 
(change between V1 and V2) and treatment group (CPAP/sham), as well as their interaction. 
Missing data were tested to ensure they were missing at random. The level of statistical 
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significance was set at 0.05. Statistical analysis was performed using SAS 9.4 (SAS Institute 
Inc., Cary, NC, USA).
RESULTS
Subjects
Eighty-four subjects were approached for the study; 25 were excluded based on screening 
criteria. Two subjects (one in each group) were lost to follow-up, two (one in each group) 
did not tolerate the equipment and two (one in each group) did not undergo MCh challenge 
at V2 due to the presence of asthma symptoms. The demographic characteristics, baseline 
measurements at V1 and type of asthma controller medication for those who completed 
follow-up (CPAP = 27; sham = 28) are summarized in Table 1. There were no statistically 
significant differences in age, sex, race or BMI; however, subjects in the sham group were 
significantly taller when height was expressed as z-scores. There were no statistically 
significant differences between groups in baseline FEV1, PC20, eNO and ACT score; 
however, the CPAP compared to sham group had a greater frequency of subjects in asthma 
treatment step 5 than in step 4.
Primary outcome: PC20
Both groups tended to have an increase in PC20 (lower airway reactivity) between V1 and 
V2, but the change did not reach statistical significance (P = 0.083). While there was a 
tendency for greater increase in PC20 in the CPAP compared to sham group, the difference 
was not statistically significant (P > 0.5) (Table 2A, Fig. 1).
The CPAP group used the machine for an average of 27.5 ± 9.4 days, 5.7 ± 1.2 days/week 
and 6.8 ± 2.2 h/night, whereas subjects in the sham group had averages of 25.3 ± 6.2 days, 
5.8 ± 1.1 days/week and 7.9 ± 1.4 h/night. There were no statistically significant differences 
in the average number of days or average days/week of machine use (Mann–Whitney U-test, 
P = 0.397 and P > 0.5, respectively). However, on average, the CPAP group used the 
machine for significantly fewer hours/night over the course of the study compared to sham 
group (unpaired t-test, P = 0.031). Eight subjects in the CPAP group (29.6%) and nine 
subjects in the sham group (32.1%) did not meet the adherence criteria, which was not 
statistically different (chi-square test, P > 0.5).
The primary analysis was repeated adjusting for adherence by excluding the 17 non-adherent 
subjects, as well as adjusting for total hours of machine use, height z-scores and asthma 
treatment step. None of the subanalyses significantly altered the results.
Adverse events—There was no significant difference between groups for subjects with 
asthma exacerbations treated with oral corticosteroids (5 CPAP:3 sham; Fisher’s exact test, P 
> 0.5). Repeating the primary analysis with the exclusion of these subjects did not 
significantly alter the results.
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Secondary outcomes
The overall success rate in obtaining quality sputum samples was 57%; however, only 12 
sham and 10 CPAP subjects had quality samples at both study visits. At V1, there were no 
significant differences between the two groups in total cell count per gram of sputum (×106) 
or % eosinophils (3.4 vs 4.6, P > 0.5; and 6.2 vs 3.9, P > 0.5, respectively). While there was 
a tendency for % eosinophils to decrease in CPAP group and to increase in sham group, the 
changes for the groups were not significantly different (P = 0.130) (Table 2B, Fig. 2).
Cytokines levels of IL-5, IL-13, IL-8, IL-10, interferon-gamma (IFN-γ) and TNF-α in the 
induced sputum supernatant did not change significantly with treatment and there were no 
significant differences in the changes between treatment groups (Table 3).
FEV1, eNO and ACT score did not change significantly with treatment and there were no 
significant differences in the changes between treatment groups (Table 4).
DISCUSSION
We hypothesized that the 4-week treatment with nocturnal CPAP would markedly suppress 
airway reactivity, producing a twofold increase in PC20 in children with moderate–severe 
asthma, similar to that observed in adults with mild well-controlled asthma treated for 1 
week. We did not find a significant effect of CPAP treatment in children with moderate–
severe asthma, although there was a tendency for a greater increase in PC20 compared to 
sham-treated children. There was also a tendency for a decrease in airway inflammation in 
CPAP-treated subjects, which also did not reach statistical significance. Our findings suggest 
that the magnitude of suppression of airway reactivity following 1 month of CPAP treatment 
in children with moderate–severe asthma is much smaller than in adults with mild well-
controlled asthma.13
There are several possible explanations for our current findings. The sample size for our 
children was based upon our previous adult data with an effect size required to double PC20. 
As there was no published data to obtain better estimates in children with moderate–severe 
asthma, we used data from our previous study of adults with mild asthma treated for 1 week 
to power the current study. A twofold magnitude of suppression of airway reactivity would 
be of a magnitude observed with pharmacological interventions,20–22 and less than the PC20 
variability reported for repeated measurements in children.23 While 1-month intervention 
might result in greater variability than 1-week intervention, it might have also produced a 
greater treatment effect. We observed a much smaller potential effect size in children with 
moderate–severe asthma, which was not statistically significant with the number of subjects 
we evaluated. Our results indicate that children with moderate–severe asthma treated with 
CPAP for 1 month produces a much smaller suppression of airway reactivity than adults 
with mild well-controlled asthma treated for 1 week.
The smaller effect size we observed in children with moderate–severe asthma compared to 
adults with mild well-controlled asthma may relate to airway remodelling that often occurs 
with more severe disease.24 Airway remodelling may increase airway stiffness, limiting the 
degree of mechanical strain CPAP delivers to the airways and ASM. This mechanism may 
PRACA et al. Page 5
Respirology. Author manuscript; available in PMC 2019 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
also explain the smaller bronchodilating effect produced by deep inspiration in adults with 
asthma compared to non-asthmatic controls.3 The children in our study also used medium-
high dose ICS, which might impair the molecular pathways by which mechanical strain 
suppresses ASM reactivity. In addition, differences in autonomic modulation between non-
asthma and asthmatic children might contribute to suppression of in vivo airway reactivity.25
Lack of adherence to treatment can contribute to the absence of a treatment effect. A 
multicentre study evaluating adult subjects with mild well-controlled asthma found that 
CPAP for 12 weeks suppressed airway reactivity23; however, sham treatment had a similar 
effect. In that study, adherence to treatment was very low and significantly lower in CPAP 
(36%) versus sham (52%), which may have accounted for the absence of a significant 
difference between treatment groups. In our current study, we had good adherence for both 
groups (70%), which is higher than 50% adherence reported with regular asthma 
medications,26 and our outcomes were similar when adjusted for adherence. Therefore, poor 
adherence does not appear to account for the absence of a CPAP effect in our study. 
However, adherence was defined as >4 h/night, derived from CPAP usage for obstructive 
sleep apnoea. It remains unclear as to the number of hours/night or length of CPAP 
treatment required to markedly suppress airway reactivity in subjects with moderate–severe 
asthma.
Our observation that CPAP and sham tend to suppress airway reactivity, but did not reach 
statistical significance, was similar to a larger multicentre study of adults.27 In both studies, 
sham was used as the control treatment and no group used neither CPAP nor sham. 
Therefore, improvements with time may have been secondary to greater adherence with 
asthma medications during the study, due to the Hawthorne effect, or a potential benefit of 
nocturnal warm, humidified and filtered air provided by the equipment.
Sample size was important for our evaluation of whether mechanical strain suppressed 
airway inflammation, as observed previously in our in vitro studies.11,12 We obtained 60% 
success rate for good quality sputum samples, similar to previous studies of children28,29; 
however, only a few children (10–12) had quality sputum at both visits. With limited 
longitudinal samples, we did not observe a significant decrease in airway inflammation with 
CPAP treatment; however, trends towards a suppression in airway inflammation provides 
important translational pilot data, which does not exist in the literature, to further test this 
novel hypothesis with a larger study population.
A strength of our study is that it is the first to evaluate CPAP therapy to suppress airway 
reactivity and inflammation in children, particularly those with moderate–severe asthma who 
would greatly benefit if corticosteroid use could be reduced. Another strength was the good 
adherence to treatment, particularly as we were evaluating children from 8 to 17 years of 
age.
Our study had several limitations. As we evaluated only children with moderate–severe 
asthma, the results cannot be extrapolated to children with mild or moderate asthma. A 
major limitation of our study was the limited number of subjects we could recruit from a 
single paediatric centre; however, we were able to evaluate whether this population 
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demonstrated a suppression of airway reactivity of a magnitude similar to what we 
previously observed in adults with mild well-controlled asthma. The smaller effect size in 
the current study would require 132 subjects/group to achieve statistical significance. Our 
evaluation of airway inflammation was limited to induced sputum rather than 
bronchoalveolar lavage, which would not have been an acceptable risk in our children.
In summary, 4 weeks of CPAP treatment for children with moderate–severe asthma did not 
markedly suppress airway reactivity to the degree we previously observed in adults with 
well-controlled mild asthma, nor did it significantly suppress airway inflammation.
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SUMMARY AT A GLANCE
We compared 4 weeks of nocturnal continuous positive airway pressure (CPAP) versus 
sham to suppress airway reactivity and inflammation in children with moderate–severe 
asthma. There were no significant differences between treatments. The treatment effect in 
children with moderate–severe asthma was smaller than previously reported in adults 
with mild well-controlled asthma.
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Figure 1. 
Airway reactivity (PC20) at visit 1 and visit 2 for continuous positive airway pressure 
(CPAP; , n = 26) and (sham; , n = 27) treated groups. There was no significant 
difference between treatment groups in baseline PC20 (P > 0.5). Both groups tended to have 
an increase in PC20 (lower airway reactivity) between visit 1 and visit 2, which was not 
significant (P = 0.083). While there was a tendency for greater increase in PC20 in the 
CPAP-treated group compared to the sham-treated group, the interaction term was not 
significant (P = 0.569). Plots represent mean and SE.
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Figure 2. 
Percentage of sputum eosinophils at visit 1 and visit 2 for continuous positive airway 
pressure (CPAP; , n = 10) and (sham; , n = 12) treated groups. There was no 
signifi-cant difference between groups in baseline % sputum eosinophils (P > 0.5). While 
there was a tendency for % sputum eosinophils to decrease in the CPAP group and increase 
in the sham group between visit 1 and visit 2, the interaction term was not significant (P = 
0.130). Plots represent mean and SE.
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Table 1
Demographic characteristics and baseline measurements
Variable CPAP Sham P-value†
Subjects (#) 27 28 –
Age (years) 11.1 (2.5) 11.7 (2.5) 0.337
Males, #(%) 17 (63) 16 (57) 0.660
Race, # African American (%) 10 (37) 8 (29) 0.531
Height (cm) 142.9 (12.8) 149.7 (13.1) 0.055
Height (z-scores) −0.3 (0.9) 0.3 (0.8) 0.009
BMI (kg/m2) 18.6 (3.7) 20.5 (4.3) 0.081
BMI (z-scores) 0.2 (1.1) 0.6 (1.1) 0.112
Baseline measurements
 FEV1 (% predicted) 88.0 (12.1) 86.8 (10.0) 0.694
 PC20 (mg/mL) 2.9 (4.5) 3.2 (4.3) 0.429
 eNO (ppb) 24.2 (25.8) 28.3 (22.5) 0.235
 ACT score 20.7 (3.8) 18.9 (3.9) 0.076
Asthma treatment step‡ 0.014
# of subjects (%)
 Step 4 (medium-dose ICS + LABA/LTRA) 22 (81) 14 (50) –
 Step 5 (high-dose ICS + LABA/LTRA) 5 (19) 14 (50) –
Values are mean (SD) for all variables, except sex and race, which are represented by frequency and percentage of the given category.
†Unpaired t-test for continuous normal variables, Mann– Whitney U-test for non-normal variables and chi-square or Fisher’s exact test for 
categorical variables.
‡According to the stepwise approach to asthma treatment proposed by the NAEPP/EPR III guidelines.
ACT, Asthma Control Test; BMI, body mass index; CPAP, continuous positive airway pressure; eNO, exhaled nitric oxide; FEV1, forced expiratory 
volume in 1 s; ICS, inhaled corticosteroid; LABAs, Long-Acting Beta Agonists; LTRA, leukotriene receptor antagonists; NAEPP/EPR, National 
Asthma Education and Prevention Program/Expert Panel Report; PC20, provocative concentration to decrease FEV1 by 20%.
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